Allen Davidoff
Founder chez XORTX THERAPEUTICS INC.
Fortune : 251 441 $ au 31/03/2024
Profil
Allen Warren Davidoff was the founder of Trillium Therapeutics ULC, founded in 2004, where he held the title of Vice President-Product Development from 2004 to 2011.
He is also the founder of XORTX Therapeutics, Inc., founded in 2018, where he currently holds the titles of President, Chief Executive Officer & Director.
Dr. Davidoff's current job is as President, Chief Executive Officer & Director at XORTX Pharma Corp.
since 2012.
He previously worked at Correvio Pharma Corp.
as Head-Pharmacology & Senior Scientist from 2003 to 2004.
Dr. Davidoff received a doctorate degree from the University of Calgary in 2002.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XORTX THERAPEUTICS, INC.
3,40% | 04/03/2024 | 67 957 ( 3,40% ) | 251 441 $ | 31/03/2024 |
Postes actifs de Allen Davidoff
| Sociétés | Poste | Début |
|---|---|---|
| XORTX THERAPEUTICS INC. | Founder | 09/01/2018 |
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Chief Executive Officer | 01/07/2012 |
Anciens postes connus de Allen Davidoff
| Sociétés | Poste | Fin |
|---|---|---|
| CORREVIO PHARMA CORP. | Chief Tech/Sci/R&D Officer | 01/12/2004 |
| TRILLIUM THERAPEUTICS | Founder | - |
Formation de Allen Davidoff
| University of Calgary | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| XORTX THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Correvio Pharma Corp.
 Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Health Technology |
